Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment

Although ibrutinib is highly effective in Waldenstrom macroglobulinemia (WM), no complete remissions in WM patients treated with ibrutinib have been reported to date. Moreover, ibrutinib-resistant disease is being steadily reported and is associated with dismal clinical outcome (overall survival of...

Descripción completa

Detalles Bibliográficos
Autores principales: Paulus, A, Akhtar, S, Yousaf, H, Manna, A, Paulus, S M, Bashir, Y, Caulfield, T R, Kuranz-Blake, M, Chitta, K, Wang, X, Asmann, Y, Hudec, R, Springer, W, Ailawadhi, S, Chanan-Khan, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518884/
https://www.ncbi.nlm.nih.gov/pubmed/28548645
http://dx.doi.org/10.1038/bcj.2017.40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518884/
https://www.ncbi.nlm.nih.gov/pubmed/28548645
http://dx.doi.org/10.1038/bcj.2017.40

Ejemplares similares